Debio 1453
Alternative Names: Debio-1453; Debio-1453PLatest Information Update: 02 Jul 2025
At a glance
- Originator Debiopharm; Nobelex Biotech
- Class Antibacterials; Small molecules
- Mechanism of Action Enoyl ACP reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gonorrhoea
Most Recent Events
- 25 Jun 2025 Debiopharm plans a first-in-human phase I trial in Healthy adult volunteers (PO, Solution) (NCT07035769) (EudraCT2024-519328-26)
- 28 May 2025 Debiopharm plans a phase I and phase II trial for Neisseria gonorrhoeae infections
- 28 May 2024 No recent reports of development identified for preclinical development in Gonorrhoea in Switzerland (PO)